US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Corgi Beauty, Skincare & Aesthetics ETF

28.50

+0.39691.41%

Volume:341

Turnover:10K

Market Cap:1.43M

PE:- -

High:28.50

Open:28.45

Low:28.45

Close:28.11

52wk High:29.89

52wk Low:24.32

Shares:50.00K

Float Shares:50.00K

Volume Ratio:2.91

T/O Rate:0.68%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Genmab Says Phase 3 Epcore DLBCL-2 Trial Shows Epcoritamab Plus R-CHOP Cuts Progression or Death Risk 51% in Newly Diagnosed DLBCL

Moderately bullish activity in Hims and Hers Health with shares up 3.07%

Genmab - Phase 3 Trial Shows 51% Reduction in Risk of Progression or Death in Dlbcl

THOMSON REUTERS

Genmab: Safety Profile of Epcoritamab When Administered in Combination with Standard of Care R-Chop was Generally Well Tolerated

THOMSON REUTERS

Genmab and Abbvie Announce Epcoritamab in Combination with R-Chop Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

THOMSON REUTERS

Estee Lauder Raised to Overweight from Equal-Weight by Barclays

Align Slips as Brokerage Downgrades Rating to 'in Line' over Slowing Demand

Align Technology, Inc. : Evercore Isi Cuts to in Line from Outperform; Cuts Target Price to $155 from $220

THOMSON REUTERS

U.S. Stocks on the MOVE-Estée Lauder, PTC, Vaxcyte

Evercore ISI Downgrades Align Technology to In Line From Outperform

MT Newswires Live

Align Technology downgraded to In Line from Outperform at Evercore ISI

Estée Lauder up After Barclays Upgrades to 'overweight'

The EstÉE Lauder Companies : Barclays Raises Target Price to $108 from $97

THOMSON REUTERS

Shares of Estee Lauder up 1.6% Premarket After Barclays Upgrades to 'Overweight'

THOMSON REUTERS

US Research Roundup-Danaher Corporation, Illumina, Reliance

Is Hims & Hers Health (HIMS) A Bargain After The Fraud Lawsuit Claims?

Simply Wall St.

Is New Regional CMOs Altering The Investment Case For Hims & Hers Stock (HIMS)?

Simply Wall St.

Align Technology Inc. Stock Underperforms Friday When Compared to Competitors

AbbVie Joins US Government Pilot to Test Drug Discount Rebates

Hims & Hers Chief Legal Officer Soleil Boughton Disposes of 3,461 Common Shares Worth $100,964.37

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/GLAM/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GLAM","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLAM\",,,,,undefined,":{"symbol":"GLAM","market":"US","secType":"STK","nameCN":"Corgi Beauty, Skincare & Aesthetics ETF","latestPrice":28.5044,"timestamp":1791576000000,"preClose":28.1075,"halted":0,"volume":341,"delay":0,"changeRate":0.014120786267010537,"floatShares":50000,"shares":50000,"eps":0,"marketStatus":"Closed","change":0.3969,"latestTime":"10-09 16:00:00 EDT","open":28.45,"high":28.5044,"low":28.4499,"amount":9716,"amplitude":0.001939,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":5,"adr":0,"exchange":"CBOE","adjPreClose":28.1075,"nav":28.11,"aum":1405500,"bidAskSpread":0,"volumeRatio":2.909555,"impliedVol":0.1031,"impliedVolPercentile":0.1},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLAM\",,,,,undefined,":{"symbol":"GLAM","floatShares":50000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":2.909555,"shares":50000,"dividePrice":0,"high":28.5044,"amplitude":0.001939,"preClose":28.1075,"low":28.4499,"week52Low":24.3178,"pbRate":"--","week52High":29.89,"institutionHeld":0,"latestPrice":28.5044,"eps":0,"divideRate":0,"volume":341,"delay":0,"ttmEps":0,"open":28.45,"prevYearClose":25.82,"prevWeekClose":27.6182,"prevMonthClose":27.766,"prevQuarterClose":27.766,"fiveDayClose":27.6182,"twentyDayClose":28.0254,"sixtyDayClose":27.8939},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GLAM\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GLAM\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GLAM\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GLAM\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673089429","title":"Genmab Says Phase 3 Epcore DLBCL-2 Trial Shows Epcoritamab Plus R-CHOP Cuts Progression or Death Risk 51% in Newly Diagnosed DLBCL","url":"https://stock-news.laohu8.com/highlight/detail?id=2673089429","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673089429?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:50","pubTimestamp":1791226259,"startTime":"0","endTime":"0","summary":"Genmab says Phase 3 EPCORE DLBCL-2 trial shows epcoritamab plus R-CHOP cuts progression or death risk 51% in newly diagnosed DLBCLGenmab, AbbVie reported positive topline Phase 3 results for epcoritam","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDLWBPbl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","IE00B19Z3B42.SGD","LU1585245621.USD","AGNG","LU0320765646.SGD","LU2468319806.SGD","IE000SO60NU8.SGD","IE000WAW04H5.SGD","FHLC","IE00BKPKM429.USD","LU0310799852.SGD","IE00BJT1NW94.SGD","BK4550","FTXH","XLV","LU2095319765.USD","LU0234570918.USD","TRUH","BCDF","LU0158827948.USD","ABBV","BK4581","IE00BN0W2V16.EUR","LU0289961442.SGD","LU0912757837.SGD","PJP","JDOC","LU1720051017.SGD","MEDX","IE00B2B36J28.USD","LU0114720955.EUR","LU0859254822.USD","IE00B19Z3581.USD","RXL","IXJ","IE00BQXX3F31.USD","LU1003077747.HKD","PPH","IYH","VHT","LU0198837287.USD","LU0943347566.SGD","IE00BGHQF748.EUR","LU1923622614.USD","LU0882574055.USD","BK4588","LU1989771016.USD","NDAQ","LU2089283258.USD","GLAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673081372","title":"Moderately bullish activity in Hims and Hers Health with shares up 3.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2673081372","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673081372?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:50","pubTimestamp":1791226213,"startTime":"0","endTime":"0","summary":"Moderately bullish activity in Hims and Hers Health (HIMS), with shares up 89c, or 3.07%, near $29.89. Options volume roughly in line with average ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-hims-and-hers-health-with-shares-up-3-07-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderately-bullish-activity-in-hims-and-hers-health-with-shares-up-3-07-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLAM","HMYY","HIMY","HIMZ","BK4196","HIMS","HEAL","HIYY","HIMC","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673894940","title":"Genmab - Phase 3 Trial Shows 51% Reduction in Risk of Progression or Death in Dlbcl","url":"https://stock-news.laohu8.com/highlight/detail?id=2673894940","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673894940?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:49","pubTimestamp":1791226144,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R1GV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1023059063.AUD","IE00B19Z3B42.SGD","LU0456855351.SGD","LU1585245621.USD","AGNG","LU0320765646.SGD","LU2468319806.SGD","IE000SO60NU8.SGD","IE000WAW04H5.SGD","FHLC","LU0310799852.SGD","IE00BJT1NW94.SGD","BK4550","LU1551013425.SGD","FTXH","XLV","LU0234570918.USD","TRUH","LU0158827948.USD","ABBV","BK4581","LU0289961442.SGD","LU0912757837.SGD","IE0000B7K699.USD","PJP","JDOC","LU1720051017.SGD","MEDX","IE00BBT3K403.USD","IE00B2B36J28.USD","LU0114720955.EUR","LU0859254822.USD","IE00B19Z3581.USD","RXL","LU0965509010.AUD","IXJ","LU1003077747.HKD","PPH","IYH","VHT","LU0198837287.USD","LU0943347566.SGD","LU1923622614.USD","LU0882574055.USD","BK4588","LU1267930573.SGD","LU0553294199.USD","LU1989771016.USD","LU2089283258.USD","GLAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673894110","title":"Genmab: Safety Profile of Epcoritamab When Administered in Combination with Standard of Care R-Chop was Generally Well Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2673894110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673894110?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:49","pubTimestamp":1791226144,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R1GV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0965509101.SGD","LU2023251221.USD","LU0738911758.USD","IE0004445239.USD","LU1244550577.SGD","BK4566","JDOC","LU1551013425.SGD","IE00BJJMRZ35.SGD","PPH","LU0795875086.SGD","LU0256863811.USD","LU2237443382.USD","TRUH","LU1548497426.USD","MEDX","RXL","BK4559","GLAM","LU0861579265.USD","ABBV","LU0128525929.USD","PJP","IE00BVYPNV92.GBP","LU0417517546.SGD","LU0708994859.HKD","LU1037948541.HKD","FTXH","XLV","IYH","LU2357627491.SGD","AGNG","FHLC","LU0456855351.SGD","LU0795875169.SGD","SG9999015952.SGD","VHT","BK4534","LU0868494617.USD","LU2129689605.HKD","LU0256863902.USD","LU0234570918.USD","IE00BJT1NW94.SGD","LU0689626769.HKD","BK4550","LU1934455194.USD","LU1989772923.USD","LU1934455277.USD","IXJ","LU0949170772.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673089491","title":"Genmab and Abbvie Announce Epcoritamab in Combination with R-Chop Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2673089491","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673089491?lang=en_us&edition=fundamental","pubTime":"2026-10-06 02:49","pubTimestamp":1791226144,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R1GV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PJP","RXL","VHT","LU0320765646.SGD","IE000BZT7R73.USD","IXJ","ABBV","LU2237443382.USD","LU1585245621.USD","TRUH","MEDX","LU0868494708.USD","LU1267930490.SGD","IE00BVYPNW00.USD","LU0965509101.SGD","LU1551013342.USD","LU2089984988.USD","IE000SO60NU8.SGD","GLAM","IYH","LU2087621335.USD","LU2089284900.SGD","LU1989772840.SGD","FHLC","LU1934455277.USD","LU1934455863.HKD","LU1093756168.USD","IE00B3PB1722.GBP","LU2433249047.HKD","IE00B19Z3B42.SGD","LU2129689605.HKD","LU0511384066.AUD","LU1923622614.USD","FTXH","LU0868494617.USD","XLV","LU1037948897.HKD","LU1236620750.USD","LU1267930573.SGD","LU0820561909.HKD","PPH","BK4585","LU2112291526.USD","LU2129689514.USD","JDOC","LU1023059063.AUD","LU0823416689.USD","AGNG","LU1720051108.HKD","LU0689472784.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673091707","title":"Estee Lauder Raised to Overweight from Equal-Weight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2673091707","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673091707?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:59","pubTimestamp":1791205140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EL/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0690374615.EUR","BK4585","LU2264538146.SGD","LU2552382058.USD","BK4533","EL","GLAM","LU0690374961.EUR","LU2552382215.SGD","BK4558","BK4504","BK4183","BK4548","LU1064131342.USD","LU2552382132.HKD","LU1988902786.USD","BK4588","LU2404859667.USD","LU2404859741.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673970407","title":"Align Slips as Brokerage Downgrades Rating to 'in Line' over Slowing Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2673970407","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673970407?lang=en_us&edition=fundamental","pubTime":"2026-10-05 19:37","pubTimestamp":1791200244,"startTime":"0","endTime":"0","summary":"BUZZ-Align slips as brokerage downgrades rating to 'in line' over slowing demand** Shares of Align TechnologyALGN.Ofall 3% to $139.45 premarket** Brokerage Evercore ISI cuts ALGN's rating to \"in line\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL4N45R0NV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","BK4198","EVR","LU2023250843.SGD","LU1974910355.USD","BK4127","ALGN","BK4534","LU2106854487.HKD","LU2023250504.SGD","BK4504","BK4588","GLAM","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673770110","title":"Align Technology, Inc. : Evercore Isi Cuts to in Line from Outperform; Cuts Target Price to $155 from $220","url":"https://stock-news.laohu8.com/highlight/detail?id=2673770110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673770110?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:45","pubTimestamp":1791197121,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R0SQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLAM","ALGN","LU1917777945.USD","BK4504","BK4198","BK4534","BK4585","LU1974910355.USD","LU2023250843.SGD","LU2023250504.SGD","LU2106854487.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673013957","title":"U.S. Stocks on the MOVE-Estée Lauder, PTC, Vaxcyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2673013957","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673013957?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:30","pubTimestamp":1791196242,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Estée Lauder, PTC, VaxcyteOct 5 -U.S. stock index futures dipped on Monday, as technology stocks took a breather after touching record highs, while investors looked for fresh clues on the monetary policy path with Treasury yields and oil prices still elevated..N** VaxcytePCVX.O:BUZZ - Vaxcyte surges on pneumococcal vaccine late-stage trial successnL4N45R0K0** Estée LauderEL.N:BUZZ - Estée Lauder up after Barclays upgrades to 'overweight'nL6N45R0HX** PTCPTC.O:BUZZ - PTC surges after Schneider Electric agrees to $22.6 bln buyout dealnL6N45R0HV","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL6N4500LU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1951200564.SGD","BK4139","LU2506951875.HKD","EL","LU1721428347.USD","BK4504","BK4183","LU2404859741.USD","LU2362540622.SGD","BK4585","LU1951198990.SGD","LU2506952410.USD","LU2552382132.HKD","BK4023","LU2404859667.USD","IE0009354923.USD","PCVX","LU2477742899.HKD","LU0823417737.USD","LU0690374961.EUR","LU2506952097.USD","LU0950375773.USD","LU2552382058.USD","GLAM","LU1988902786.USD","SG9999014005.SGD","LU0690374615.EUR","SG9999014021.USD","LU2506952337.HKD","BK4576","BK4588","LU2552382215.SGD","LU2362541513.USD","LU0053671581.USD","BK4558","LU2506951958.HKD","LU2264538146.SGD","LU1064131342.USD","SG9999014013.SGD","LU0823417653.USD","BK4554","LU2362541273.HKD","PTC","BK4548","LU2506952170.USD","LU1923623000.USD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673706062","title":"Evercore ISI Downgrades Align Technology to In Line From Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2673706062","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673706062?lang=en_us&edition=fundamental","pubTime":"2026-10-05 17:47","pubTimestamp":1791193667,"startTime":"0","endTime":"0","summary":"Align Technology (ALGN) has an average rating of overweight and mean price target of $207.23, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LU2106854487.HKD","LU1974910355.USD","GLAM","BK4588","BK4534","LU1917777945.USD","LU2023250843.SGD","BK4504","ALGN","LU2023250504.SGD","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673706761","title":"Align Technology downgraded to In Line from Outperform at Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2673706761","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673706761?lang=en_us&edition=fundamental","pubTime":"2026-10-05 17:30","pubTimestamp":1791192608,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Elizabeth Anderson downgraded Align Technology (ALGN) to In Line from Outperform with a price target of $155, down from $220. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/align-technology-downgraded-to-in-line-from-outperform-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/align-technology-downgraded-to-in-line-from-outperform-at-evercore-isi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4198","LU2023250504.SGD","LU1917777945.USD","BK4585","LU2106854487.HKD","LU1974910355.USD","GLAM","LU2023250843.SGD","BK4504","ALGN","BK4588","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673586706","title":"Estée Lauder up After Barclays Upgrades to 'overweight'","url":"https://stock-news.laohu8.com/highlight/detail?id=2673586706","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673586706?lang=en_us&edition=fundamental","pubTime":"2026-10-05 17:18","pubTimestamp":1791191916,"startTime":"0","endTime":"0","summary":"BUZZ-Estée Lauder up after Barclays upgrades to 'overweight'** Shares of cosmetics maker Estée LauderEL.Nup 2.2% at $93.98 premarket** Brokerage Barclays upgrades stock to \"overweight\" from \"equal weight\"; raises PT to $108 from $97** Says co's projected sales growth, earnings profile over next several years make it among the most attractive companies in the broader global consumer staples index** Notes that after seven quarters since unveiling its turnaround plan, codeliveredmore balanced revenue growth, against expectations that reshaping its operating model would require significant time and investment** Notes growth across regions, sees North America growth to remain elevated in current quarter, structural changes to the operating model could support continued reinvestment while driving EBIT margins into the high teens over time** Average rating of 44 brokerages is \"buy\"; with a median PT of $129- data compiled by LSEG** Up to last close, stock has fallen ~12% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL6N45R0HX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","LU2552382058.USD","LU2552382215.SGD","LU0690374961.EUR","BK4588","EL","BK4183","BK4548","LU1988902786.USD","BK4558","BK4585","LU2404859741.USD","BK4504","LU0690374615.EUR","LU2404859667.USD","LU2264538146.SGD","BK4533","LU2552382132.HKD","GLAM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673705784","title":"The EstÉE Lauder Companies : Barclays Raises Target Price to $108 from $97","url":"https://stock-news.laohu8.com/highlight/detail?id=2673705784","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673705784?lang=en_us&edition=fundamental","pubTime":"2026-10-05 17:00","pubTimestamp":1791190829,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nAZN4TND62:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2404859667.USD","EL","LU1988902786.USD","BK4504","BK4588","BK4585","LU0690374615.EUR","BK4183","BK4548","LU0690374961.EUR","GLAM","LU2404859741.USD","LU1064131342.USD","LU2552382058.USD","BK4558","LU2552382215.SGD","BK4533","LU2552382132.HKD","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673705234","title":"Shares of Estee Lauder up 1.6% Premarket After Barclays Upgrades to 'Overweight'","url":"https://stock-news.laohu8.com/highlight/detail?id=2673705234","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673705234?lang=en_us&edition=fundamental","pubTime":"2026-10-05 16:59","pubTimestamp":1791190762,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45Q03W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2404859667.USD","LU1064131342.USD","BK4504","BK4588","LU0690374961.EUR","EL","LU1988902786.USD","BK4585","BK4558","LU2552382132.HKD","LU2552382215.SGD","GLAM","BK4533","LU2404859741.USD","LU2552382058.USD","LU2264538146.SGD","BK4183","BK4548","LU0690374615.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673770360","title":"US Research Roundup-Danaher Corporation, Illumina, Reliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2673770360","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673770360?lang=en_us&edition=fundamental","pubTime":"2026-10-05 15:55","pubTimestamp":1791186918,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Danaher Corporation, Illumina, RelianceOct 5 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Danaher C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nL4N45R0DS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMD","AMDY","CHRW","CL","WUGI","AR","BSX","AGCO","AMG","SMH","CAT","BANC","AMRZ","CHD","BXP","AESI","APO","COF","AOSL","GPZ","GLAM","KROP","BFAM","CME","AB","ACM","ALL","ARCB","BAM","BNY","OZK","AMBQ","DHR","CTRE","AXP","CE","CBOE","ALGN","BLK","ASB","BX","CG","FEAM","ADP","AUB","CHRD","XNTK","AIS","BP","ARES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672727360","title":"Is Hims & Hers Health (HIMS) A Bargain After The Fraud Lawsuit Claims?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672727360","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672727360?lang=en_us&edition=fundamental","pubTime":"2026-10-04 14:18","pubTimestamp":1791094706,"startTime":"0","endTime":"0","summary":"Hims & Hers Health (HIMS) is back in focus after a proposed securities fraud class action accused the telehealth provider of misleading investors about data sharing practices and prescription billing workflows.\nRecent price action for Hims & Hers Health has been choppy, with the share price slipping about 1% over the past day and week, climbing 4.7% over the past month, yet falling 24.2% across 90 days. The 1-year total shareholder return is down 44.8%, despite a very large 3-year gain that...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6032000-choice2-card/1788952998790","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6032000-choice2-card/1788952998790"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/is-hims-hers-health-hims-a-bargain-after-the-fraud-lawsuit-c","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/is-hims-hers-health-hims-a-bargain-after-the-fraud-lawsuit-c","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HEAL","HIMS","HMYY","GLAM","HIYY","THNR","BK4196","HIMY","HIMC","HIMZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672474757","title":"Is New Regional CMOs Altering The Investment Case For Hims & Hers Stock (HIMS)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672474757","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672474757?lang=en_us&edition=fundamental","pubTime":"2026-10-03 10:18","pubTimestamp":1790993925,"startTime":"0","endTime":"0","summary":"Hims & Hers Health recently appointed Kultar Garcha as Chief Medical Officer for the UK and EMEA and Matt Vickers as Chief Medical Officer for Australia, expanding local clinical leadership across key international regions.\nThe move concentrates experienced physicians on clinical quality, patient safety, and prescribing standards, which directly influences how effectively the business can scale personalized care across multiple markets.\nWe will now look at how these new regional Chief...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6032000-choice2-card/1788952998790","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6032000-choice2-card/1788952998790"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/is-new-regional-cmos-altering-the-investment-case-for-hims-h","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-hims/hims-hers-health/news/is-new-regional-cmos-altering-the-investment-case-for-hims-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4196","HIMS","HEAL","GLAM","HIMY","HIYY","HMYY","HIMZ","THNR","HIMC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672741375","title":"Align Technology Inc. Stock Underperforms Friday When Compared to Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2672741375","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672741375?lang=en_us&edition=fundamental","pubTime":"2026-10-03 05:17","pubTimestamp":1790975820,"startTime":"0","endTime":"0","summary":"DJ Align Technology Inc. Stock Underperforms Friday When Compared To CompetitorsThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Align Technology Inc.  slipped 1.10% to $143.74 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 0.73% to 7,722.72 and the Dow Jones Industrial Average  rising 0.49% to 51,176.96.This was the stock's second consecutive day of losses.Align Technology Inc. closed 28.29% below its 52-week high of $200.44, which the company reached on April 21st.The stock underperformed when compared to some of its competitors Friday, as Zimmer Biomet Holdings Inc.  rose 0.26% to $88.29 and Dentsply Sirona Inc.  fell 0.80% to $8.67.Trading volume  remained 365,951 below its 50-day average volume of 915,090.Data source: Dow Jones Market Data, FactSet. Data compiled October 2, 2026.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0477156953.USD","LU1201861249.SGD","LU0211328371.USD","LU1917777945.USD","LU1974910355.USD","IE00B19Z3581.USD","LU0792757196.USD","IE00B7SZLL34.SGD","LU0648001328.SGD","BK4534","LU2106854487.HKD","BK4588","LU0211327993.USD","LU2023250504.SGD","GLAM","BK4566","LU0980610538.SGD","IE0002270589.USD","LU1267930573.SGD","LU2023250843.SGD","LU0889566641.SGD","LU1267930490.SGD","LU0029864427.USD","BK4585","ALGN","LU0130102774.USD","LU0310799852.SGD","XRAY","ZBH","LU0130517989.USD","LU0006061336.USD","LU0708994859.HKD","LU1267930813.SGD","BK4504","LU0128525929.USD","BK4198","LU0310800379.SGD","IE00B19Z3B42.SGD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672749758","title":"AbbVie Joins US Government Pilot to Test Drug Discount Rebates","url":"https://stock-news.laohu8.com/highlight/detail?id=2672749758","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672749758?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:51","pubTimestamp":1790974284,"startTime":"0","endTime":"0","summary":"AbbVie joins US government pilot to test drug discount rebatesOct 2 -US drugmaker AbbVieABBV.Nsaid on Friday it would participate in a US government pilot program aimed at testing a new rebate system for discounted medicines.Here are some details:The pilot will begin on January 1, 2027, under the government's 340B program, which helps hospitals and clinics serving low-income patients buy medicines at a discount.Under the new model, eligible healthcare providers will submit claims through a platform called Beacon to obtain 340B pricing on AbbVie's cancer drug Imbruvica, irritable bowel syndrome treatment Linzess and antipsychotic drug Vraylar.AbbVie said it would provide healthcare groups with free access to the system, as well as customer service and special assistance for providers facing operational difficulties.The rebate test will help improve pricing transparency and prevent duplicate discounts as new Medicare-negotiated drug prices take effect, the company said.AbbVie said it pla","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nL4N45O19X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1236620834.HKD","LU2347655156.SGD","LU0124676726.USD","LU0211327993.USD","LU0965509010.AUD","LU2237443382.USD","JDOC","LU0795875086.SGD","PPH","FHLC","LU1267930490.SGD","LU0256863811.USD","LU1732799900.SGD","FTXH","LU2089283258.USD","LU0861579265.USD","LU1291159041.SGD","LU2129689605.HKD","LU0965508806.USD","BK4581","IE000F7OJYX1.SGD","LU0661504455.SGD","LU1430594728.SGD","LU0726765562.USD","IE00B3PB1722.GBP","IE00B19Z3581.USD","LU2087621335.USD","LU0395794307.EUR","IE0000B7K699.USD","LU2023251221.USD","IE00BN8TJ469.HKD","LU1003077747.HKD","LU1244550494.USD","IE00B19Z3B42.SGD","LU0114720955.EUR","LU2237443549.SGD","IE0002141913.USD","LU0820561909.HKD","LU2129689514.USD","LU0965509101.SGD","IE0009355771.USD","LU1839511570.USD","LU1093756168.USD","IE00BSNM7G36.USD","BK4588","LU0859254822.USD","LU0320765646.SGD","LU1585245621.USD","LU0122379950.USD","LU0689626769.HKD","LU2357627491.SGD","BK4533","IE00BJJMRZ35.SGD","LU0029864427.USD","LU2125909247.SGD","LU0198837287.USD","LU1057294990.SGD","LU1267930573.SGD","ABBV","IE00BFTCPJ56.SGD","LU0708994859.HKD","AGNG","LU0170899867.USD","LU0289739343.SGD","RXL","SG9999015986.USD","LU0310800379.SGD","LU1934455277.USD","LU1929549753.HKD","LU0472753341.HKD","LU2433249047.HKD","LU2112291526.USD","IE00BLSP4452.SGD","LU1732800096.USD","IE00B42XCP33.USD","LU2237443978.SGD","LU0985320562.USD","LU0882574055.USD","LU2089984988.USD","GLAM","BK4550","IE00B2B36J28.USD","LU1037948541.HKD","LU0234572021.USD","IE0002270589.USD","LU1670627923.USD","LU0868494617.USD","LU0942090050.USD","LU1023059063.AUD","LU1923622614.USD","LU1162221912.USD","LU0545039389.USD","SG9999001440.SGD","LU1989772840.SGD","LU0738911758.USD","LU1093756325.SGD","LU1720051108.HKD","MEDX","LU2237443895.HKD","LU1989772923.USD","LU0234570918.USD","LU0912757837.SGD","LU0256863902.USD","LU1551013425.SGD","LU1670628061.USD","PJP","LU1718418525.SGD","LU2133065610.SGD","IE000WAW04H5.SGD","LU0820561818.USD","LU0310799852.SGD","LU0965509283.SGD","LU0511384066.AUD","IE00BVYPNW00.USD","LU1061106388.HKD","LU0417517546.SGD","LU2237443622.USD","LU2237443465.HKD","LU1720051017.SGD","LU0128525929.USD","SG9999015952.SGD","XLV","LU0456855351.SGD","VHT","BK4534","IE000BZT7R73.USD","LU0949170772.SGD","LU1496350502.SGD","LU1934455863.HKD","LU1548497426.USD","IE00BGHQF631.EUR","LU0158827948.USD","LU0289739699.SGD","LU0211328371.USD","LU0943347566.SGD","LU1244550577.SGD","LU1551013342.USD","IE000SO60NU8.SGD","LU0289961442.SGD","LU0203347892.USD","IE00BLSP4239.USD","IE00BBT3K403.USD","LU0689472784.USD","SG9999015945.SGD","LU1983299246.USD","LU2468319806.SGD","LU0823416689.USD","LU1244550221.USD","BK4585","LU2357305700.SGD","IE00BDGV0183.EUR","LU0069063385.USD","LU1989771016.USD","SG9999011175.SGD","LU0203345920.USD","LU0057025933.USD","LU1934455194.USD","LU2125909593.SGD","BK4566","IE000MB6IJN5.SGD","IE00B4R5TH58.HKD","IYH","SG9999003800.SGD","LU0432979614.USD","LU0868494708.USD","LU1496350171.SGD","LU1037948897.HKD","LU0795875169.SGD","LU2347655073.USD","LU1074936037.SGD","IE00BJT1NW94.SGD","LU0058720904.USD","IE00BVYPNV92.GBP","LU1236620750.USD","BK4559","TRUH","LU0098860793.USD","LU2089284900.SGD","BK4139","SG9999015978.USD","IE0004445239.USD","IXJ","LU2129689431.USD","LU0553294199.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672574960","title":"Hims & Hers Chief Legal Officer Soleil Boughton Disposes of 3,461 Common Shares Worth $100,964.37","url":"https://stock-news.laohu8.com/highlight/detail?id=2672574960","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672574960?lang=en_us&edition=fundamental","pubTime":"2026-10-03 04:33","pubTimestamp":1790973213,"startTime":"0","endTime":"0","summary":"Hims & Hers Chief Legal Officer Soleil Boughton disposes of 3,461 common shares worth $100,964.37Soleil Boughton, Chief Legal Officer at Hims & Hers Health, sold 3,461 Class A common shares on Sept. 3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL7zp4VD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Hims & Hers Chief Legal Officer Soleil Boughton Disposes of 3,461 Common Shares Worth $100,964.37","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLAM","HIYY","THNR","HIMY","HIMZ","HMYY","HIMS","HIMC","HEAL","BK4196"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}